Bulletin of Experimental Biology and Medicine

, Volume 125, Issue 1, pp 76–79 | Cite as

Biological properties of human mutant tumor necrosis factor-α

  • L. S. Sandakhchiev
  • N. V. Merzlikin
  • N. M. Pustoshilova
  • N. N. Istomina
  • L. R. Lebedev
  • M. I. Svyatchenko
  • E. D. Danilenko
  • V. I. Masycheva
  • S. V. Usova
Oncology

Abstract

Antitumor activities of tumor necrosis factor-α and its mutant analog R31Q are studied in HEp-2 and U-937 cell cultures. Cytotoxic activity of R31Q virtually does not differ from that of the initial form of tumor necrosis factor-α and its cytostatic effect was even slightly higher. The nonspecific toxicity of R31Q toward human diploid fibroblasts L-68 is lower. Comparative study of the drug pharmacokineticsin vivo showed a better preservation and higher concentration in the blood of the mutant analog of tumor necrosis factor-α.

Key Words

mutant tumor necrosis factor antitumor activity pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A. E. Korepanova, A. M. Eroshkin, V. A. Ivanisenko,et al., Molekul. Biologiya,28, No. 1, 143–149 (1994).Google Scholar
  2. 2.
    L. R. Lebedev, Yu. P. Zernov, I. S. Andreeva, and N. M. Pustoshilova,Biotechnologiya, No. 12, 19–24 (1995).Google Scholar
  3. 3.
    L. N. Shingarova, L. N. Sagaidak, R. P. Turetskaya,et al., Bioorgan. Khimiya,22, No. 4, 243–251 (1996).Google Scholar
  4. 4.
    J. A. J. Barbara, W. B. Smith, J. R. Gamble,et al., EMBO J.,13, 843–850 (1994).PubMedGoogle Scholar
  5. 5.
    M. J. Eck and S. R. Sprang,J. Biol. Chem.,264, 17595–17606 (1989).PubMedGoogle Scholar
  6. 6.
    A. L. Jones and P. Selby,Cancer Surv.,8, 817–836 (1989).PubMedGoogle Scholar
  7. 7.
    H. Loetscher, D. Stueber, D. Banner,et al., J. Biol. Chem.,268, 26350–26357 (1993).PubMedGoogle Scholar
  8. 8.
    A. Meager, H. Leung, and J. Wooley,J. Immunol. Methods,116, 1–17 (1989).PubMedCrossRefGoogle Scholar
  9. 9.
    K. J. Tracey, in:Cytokine Handbook, ed. A. Tompson (1994), pp. 289–304.Google Scholar
  10. 10.
    X. Van Ostade, J. Tavernier, T. Plange, and W. Fiers,EMBO J.,10, 827–836 (1991).PubMedGoogle Scholar
  11. 11.
    X. Van Ostade, P. Vandenabeele, B. Everaerdt,et al., Nature,361, 266–269 (1993).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1998

Authors and Affiliations

  • L. S. Sandakhchiev
    • 1
  • N. V. Merzlikin
    • 1
  • N. M. Pustoshilova
    • 2
  • N. N. Istomina
    • 1
  • L. R. Lebedev
    • 2
  • M. I. Svyatchenko
    • 1
  • E. D. Danilenko
    • 2
  • V. I. Masycheva
    • 2
  • S. V. Usova
    • 1
  1. 1.Institute of Molecular BiologyVektor State Research Center of Virology and BiotechnologyKol'tsovo
  2. 2.Research and Technological Institute of Bioactive AgentsVektor State Research Center of Virology and BiotechnologyKol'tsovo

Personalised recommendations